Back to top
more

ImmuCell (ICCC)

(Delayed Data from NSDQ)

$6.03 USD

6.03
3,258

-0.22 (-3.44%)

Updated Aug 5, 2025 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ImmuCell Upgraded to Outperform on Sales Surge & FDA Upside

by Zacks Equity Research

ICCC earns "Outperform" rating with record Q1 sales, margin gains and growth potential tied to Re-Tain's FDA progress and new product formats.

Zacks Equity Research

The Zacks Analyst Blog Highlights Alphabet, Oracle, Shell, Fossil and ImmuCell

by Zacks Equity Research

GOOGL, ORCL, and SHEL show sector strength, while microcaps FOSL and ICCC surge on strategic shifts and rising profitability.

Mark Vickery headshot

Top Research Reports for Alphabet, Oracle & Shell

by Mark Vickery

GOOGL, ORCL, and SHEL stand out with strong cloud, AI, and LNG tailwinds, despite macro and margin headwinds.

Zacks Equity Research

ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains

by Zacks Equity Research

ICCC posts record Q1 sales, returns to earnings and expands margins y/y as First Defense demand grows and production issues subside.

Zacks Equity Research

The Zacks Analyst Blog Netflix, SAP SE, Shell, Preformed Line Products and ImmuCell

by Zacks Equity Research

Netflix, SAP SE, Shell, Preformed Line Products and ImmuCell are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Netflix, SAP & Shell

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), SAP SE (SAP) and Shell plc (SHEL), as well as two micro-cap stocks Preformed Line Products Company (PLPC) and ImmuCell Corporation (ICCC).

Zacks Equity Research

ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain

by Zacks Equity Research

ImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion.

Zacks Equity Research

The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell

by Zacks Equity Research

Apple, Eli Lilly, Shopify and ImmuCell are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Apple, Eli Lilly & Shopify

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company (LLY) and Shopify Inc. (SHOP), as well as a micro-cap stock ImmuCell Corporation (ICCC).

Urbashi Dutta headshot

Zacks Initiates Coverage of ImmuCell With Neutral Recommendation

by Urbashi Dutta

Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval.

Zacks Equity Research

The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell

by Zacks Equity Research

Amazon.com, Stryker, Lam Research and ImmuCell are included in this Analyst Blog.

Zacks Equity Research

ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges

by Zacks Equity Research

ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.

Zacks Equity Research

Yes, You Can Time the Market. Find out How - August 27, 2020

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Zacks Equity Research

Timing the Market, Is it Possible? - August 07, 2020

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Zacks Equity Research

How to Time the Markets Like an Investing Pro - July 20, 2020

by Zacks Equity Research

In the long-run, does consistent market timing really matter to be a successful investor?